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ess: sburgess@mater.orSummary Monitoring devices attached to pressurised metered dose inhalers
provide an important objective measurement of patient adherence with asthma
medications in clinical and research settings. The Smart-inhaler is a relatively new
device that has not been previously validated. This study examines the accuracy of
the Smart-inhaler in a bench-top experiment and compares it with a previously
validated device, the Doser. Ten Smart-inhalers and five Dosers were actuated twice
on two occasions per day for 30 days (120 doses). Six Smart-inhalers were also
actuated 30 times in rapid succession to examine the ability of the Smart-inhaler to
detect ‘‘dumping’’. Five Smart-inhalers failed to detect the first one or two doses.
However, when the aerosol canister was placed more firmly in the device, actuating
the device in the process, the following two doses were recorded accurately in all
ten devices. Otherwise all ten Smart-inhalers and five Dosers recorded all actuations
faithfully and there were no spurious recordings. The six Smart-inhalers recorded all
30 doses delivered in rapid succession. The Smart-inhaler and Doser are both highly
accurate at measuring actuated doses and no spurious doses were recorded in an in
vitro setting.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The Smart-inhaler (Nexus 6, Auckland, NZ) is a
device that has been developed to measure
adherence with inhaled asthma medications. Ad-Elsevier Ltd. All rights reserv
8408111;
g.au (S.W. Burgess).herence is important both in clinical and research
settings. Poor adherence with asthma management
plans and treatment regimens has been associated
with poor disease control,1,2 an increased risk of
hospital admission3 and an increased mortality
rate.4 Objective monitoring of adherence is often
necessary as patient and parental reports of
adherence are often inaccurate and tend to
overestimate the number of doses of medicationed.
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Figure 1
S.W. Burgess et al.842taken.2,5,6 In addition a physician’s subjective
impressions of their patients’ adherence may be
equally unreliable.7,8
There are a number of devices that have been
developed to objectively measure adherence
with inhaled asthma medications including the
Doser (Meditrack, Hudson, MA, USA) and MDI log
(Westmed, Colorado, USA).9 Some patients who
suspect they are being monitored may discharge
their medication prior to clinical review in an
attempt to hide non-adherence, a practice some-
times referred to as ‘‘dumping’’.10 Monitoring
devices ideally should be able to monitor adherence
covertly, accurately record the time that each dose
was taken, store data over a reasonable time period
(more than 30 days), detect multiple successive
actuations (dumping), not interfere with the dose of
delivered medication and provide access to data so
that it may be downloaded to a personal computer.
The aim of this paper was to assess whether the
Smart-inhaler was able to accurately record actua-
tions using a range of pressurised metered dose
inhalers (pMDIs) distributed by GlaxoSmithKline (GSK)
compared with a known record of actuations. The
relative accuracy of the Smart-inhaler was compared
with the Doser (Meditrack, Hudson, MA), a previously
validated monitoring device. Six Smart-inhalers were
actuated in rapid succession to determine how the
Smart-inhaler would record ‘‘dumping’’.Methods
The Smart-inhaler replaces the plastic holder of a
standard pMDI (Fig. 1). It incorporates a switch that
is activated each time the canister is depressed
within the device. The devices supplied for this
study were orange, similar to a Fluticasone pMDI
(Flixotide, GSK). The device has a similar shape to a
standard pMDI with a compartment behind the
canister containing the battery and electronics.
The device connects to a laptop computer through
a cradle and serial communication link. A web-
based programme is used to configure the device,
set the device clock and download data. The
website is protected by a secure password and
data are stored centrally and on the user’s
computer. The web-based software can track
specific devices and data can be entered into the
same database from multiple trial sites. The web-
based software calculates adherence on the basis
of two doses given twice daily. A standard report
presents the number of subjects from each group,
the mean percentage of compliance and the
difference between the two groups. The graphic
function presents the mean compliance of eachgroup as a bar graph. The number of doses actuated
by each Smart-inhaler either on a daily, weekly or
annual basis may be graphed. However, data may
also be downloaded into a standard spreadsheet for
more detailed analysis.
The Doser is a monitoring device that has been
previously validated (Fig. 2).9,11 The Doser attaches
to the top of a pMDI with a plastic sleeve. It records
the number of doses actuated in a 24 h period and
also counts backwards from a pre-selected number
of doses. The Doser CT (clinical trials version) has a
45-day memory and may be set so that screen
contained within the device is blank. Data from a
Doser can be read from the screen but cannot be
downloaded for further analysis. The Doser can
attach to most products, although it does not
attach well to Sodium cromoglycate (Intal, Aven-
tis), Nedocromil sodium (Tilade, Aventis) or Ipra-
tropium bromide (Atrovent, Boehringer Ingelheim)
as the canister may not actuate effectively if used
with these devices.12Part one
Ten Smart-inhalers were configured using web-
based software as per the manufacturer’s instruc-
tions. Two devices were attached to a pMDI
containing Salbutamol 100 mg (Ventolin, GSK, Vic),
Fluticasone proprionate 50 mg (Flixotide), Flutica-
sone proprionate 125 mg, Fluticasone proprionate
50 mg/Salmeterol xinafoate 25 mg (Seretide), or
Fluticasone proprionate 125 mg/Salmeterol xinafo-
ate 25 mg.
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Figure 2
In vitro evaluation of an asthma dosing device: The smart-inhaler 843Five Doser CT devices were activated, the
number of doses was set at 200 and the device
was set in the clinical trials mode as per the
manufacturer’s instructions. The number of doses
was purposely set at a number higher than would be
used during the study to ensure that if additional
spurious doses were recorded the device would not
reach zero before the conclusion of the experi-
ment. Each Doser was attached to one of the same
five different pMDIs as above.
Each device was actuated twice on two separate
occasions during a 24 h period for 30 consecutive
days (120 doses). Each device was weighed prior to
and following each pair of actuations. This was
performed to detect if accidental actuation had
occurred between dosing and to confirm that two
doses had been actuated on each occasion. The
time of each actuation was recorded. Data from
each Smart-inhaler were downloaded and compared
with the known number and timing of actuations.
Data from the Dosers were reviewed on the screen
of the device. These data were manually entered
into a spreadsheet for comparison with the known
number and timing of actuations.Part two
Six Smart-inhalers were configured using web-
based software as per the manufacturer’s instruc-
tions. Each was attached to a pMDI containingeither Salbutamol 100 mg, Salmeterol xinafoate
25 mg (Serevent), Fluticasone proprionate 50 mg,
Fluticasone proprionate 125 mg, Fluticasone pro-
prionate 50 mg/Salmeterol xinafoate 25 mg or Fluti-
casone proprionate 125 mg/Salmeterol xinafoate
25 mg. Each pMDI was actuated 30 times in rapid
succession. Data from each device were then
downloaded onto a laptop using the web-based
software and compared with the known number of
actuations.Results
Part one
Five of the Smart-inhalers were 100% accurate with
no additional or omitted actuations. One Smart-
inhaler failed to record the first dose (Flixotide
125 mg) actuated and four Smart-inhalers failed to
record the first two actuations (Flixotide 50 mg and
Seretide 50/25 mg). However, the remainder of the
actuations in all devices was recorded and no
device had any spurious recordings. The time
stamps recorded by all Smart-inhalers were accu-
rate when compared with the manual log. All five
Dosers were 100% accurate.
The canisters were removed from all Smart-
inhalers and the set-up process was repeated to
investigate why five of the Dosers had failed to
record the first one or two actuations. In each case,
a new canister containing Seretide 50/25 mg was
inserted into a Smart-inhaler, but not pushed to the
bottom. All devices were weighed with the canister
in the device. The canister was then pushed firmly
into the devices actuating the canister in the
process. Two further doses were discharged from
each device. All devices were weighed before and
after each actuation.
Three actuations were recorded by nine devices.
However, the actuation that occurred as the
canister was inserted into the 6th device was not
recorded. The change in weight before and after
the first dose from the 6th Smart-inhaler was
68.9 mg which is reduced when compared with the
other 29 doses (mean 72.4 mg, range 70.5–75.3 mg).Part two
The six Smart-inhalers correctly recorded all 30
doses. Interestingly when actuated in quick succes-
sion the time stamp revealed the same time to the
second for all 30 doses which correlated with the
time of the first actuation.
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A number of studies have measured adherence with
inhaled asthma medications in several different
populations and reported mean levels ranging from
50% to 86%.2,6,13,14 It is possible that mean rates of
adherence within the general population are even
lower. It is recognised that patients who participate
in trials do not necessarily reflect the broader
population and that subjects often behave differ-
ently when they believe they are being observed.15
Adherence is difficult to measure objectively and
therefore its significance is often downplayed in
both research trials and clinical practice. However,
in both these settings adherence may prove to be a
crucial piece of the puzzle when examining the
failure of a treatment to have an effect or a
superior effect of one treatment over another. The
role in clinical practice may extend further.
Monitoring adherence and providing feedback may
improve adherence.16 Secondly adherence is a
marker of other important health-related beha-
viours demonstrated by the improved outcome of
patients who are more adherent within the placebo
arm of a trial.17
The Doser is a monitoring device that has been
validated in two previous studies. Simmons et al.11
reported that when the dosing histories from ten
Dosers were compared with known actuations
dosed by laboratory technicians, 96.7% were in
agreement. In this paper, 89% of disagreement
related to unrecorded actuations. A second study
by Julius et al.9 reported that when dosing histories
from six Dosers were compared with known actua-
tions, 94.3% were in agreement. In this study,
the majority of Dosers recorded additional doses
and reached zero prematurely. Once the preset
number of doses reaches zero further actuations
are not recorded. Prior to reaching this point
none of the Dosers missed any doses. It is not clear
from either study why the Dosers either failed to
record actuations or spurious actuations were
recorded.
In this study both the Smart-inhaler and Doser
proved to be extremely accurate. None of the
ten Smart-inhalers recorded any erroneous actua-
tions. The canisters fit firmly into the devices
and do not fall out. It would appear that it is
possible to trigger an actuation without the
canister being completely within the device or
activating the switch. When the 10 Smart-inhalers
were initially set up, each canister was placed in
the device gently to prevent an erroneous actua-
tion. After the first two actuations, no actuations
were missed and each actuation was recorded
with an accurate time stamp. When the set-upwas repeated and the canisters were firmly pushed
into the device no subsequent doses were missed.
Thus the missed actuations likely relate to the
manner in which the devices were set-up and this
should not occur if the canister is actuated as it is
inserted.
The Smart-inhaler offers the advantage of
a time stamp with a resolution of seconds. This
allows investigators to determine when doses
were given during the day. It also allows investiga-
tors to determine if doses were given so close
together that normal dosing would not have
been possible. When doses are actuated in quick
succession the time stamp is repeated. Both
devices only record that a dose was actuated and
not whether the medication was inhaled. The
Smart-inhaler looks more like a normal inhaler
than does a pMDI with the Doser attached.
However, all patients who are familiar with their
medication will recognise that the device is
different from a standard pMDI. We are currently
conducting a trial to investigate whether covert
monitoring is possible with the Smart-inhaler. The
other significant advantage of the Smart-inhaler is
the capacity to download data, saving time and
avoiding errors during the manual transfer of data
into a database.
The principal limitation of Smart-inhaler is the
cost. Thirty Smart-inhalers were purchased, along
with a docking station and 12 months access to a
trial database at a total cost of Aus$21,461. The
cost per device was 14 times the cost of the same
number of Dosers. Obviously this expense relates to
the technology involved and the cost of setting up
and maintaining the website and database for the
period of the trial. The cost per device is reduced if
a large number of devices is required per trial, and
hence may be more cost effective for larger-scale
clinical trials.References
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